CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
By running in a marathon or hosting a bake sale, you can make a real difference for our scientists in the fight against cancer and allow them to bring newer immunotherapies to more patients.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Numerous challenges can slow progress in finding new immune-based cancer treatments. We're solving some of the biggest challenges, accelerating promising new immunotherapies for patients.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Breakthroughs in Cancer Immunotherapy" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
We regularly host conferences and other forums that give dedicated researchers and clinicians an opportunity to gain a comprehensive overview of the immunological landscape, exchange ideas and findings, and advance the field.
The symposium series, held annually, focuses on progress in cancer immunology and immunotherapy research.
The annual meeting of the Cancer Immunotherapy Consortium (CIC) provides a forum for industry and academic leaders in cancer immuntherapy research and development.
Want to know more about what's going on at CRI? The Researcher is a publication that chronicles major CRI events, latest developments from our funded laboratories and clinics, community news, and more.